Scilight Press

Author Information

Received: 19 Dec 2022 | Accepted: 26 Jan 2023 | Published: 03 Feb 2023

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

liposome | nanomedicine | cancer | antifungal | nanocarriers | therapeutic | index | safety | efficacy

References 

• 1.
  Ventola C.L. The nanomedicine revolution: part 2: current and future clinical applications. P&T, 2012, 37(10): 582-591.
• 2.
  Ventola C.L. Progress in nanomedicine: approved and investigational nanodrugs. P&T, 2017, 42(12): 742-755.
• 3.
  Wang Y.W.; Grainger D.W. Regulatory considerations specific to liposome drug development as complex drug products. Front. Drug. Deliv., 2022, 2: 901281.
• 4.
  Bangham A.D.; Standish M.M.; Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 1965, 13(1): 238-252.
• 5.
  Bulbake U.; Doppalapudi S.; Kommineni N.; et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics, 2017, 9(2): 12.
• 6.
  Asadi K.; Gholami A. Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: a review. Int. J. Biol. Macromol., 2021, 182: 648-658.
• 7.
  Gulati M.; Bajad S.; Singh S.; et al. Development of liposomal amphotericin B formulation. J. Microencapsulation, 1998, 15(2): 137-151.
• 8.
  Liu P.; Chen G.L.; Zhang J.C. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules, 2022, 27(4): 1372.
• 9.
  Bozzuto G.; Molinari A. Liposomes as nanomedical devices. Int. J. Nanomed., 2015, 10: 975-999.
• 10.
  Beltrán-Gracia E.; López-Camacho A.; Higuera-Ciapara I.; et al. Nanomedicine review: clinical developments in liposomal applications. Cancer Nanotechnol., 2019, 10(1): 11.
• 11.
  Hou X.C.; Zaks T.; Langer R.; et al. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater., 2021, 6(12): 1078-1094.
• 12.
  Kisby T.; Yilmazer A.; Kostarelos K. Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nat. Nanotechnol., 2021, 16(8): 843-850.
• 13.
  Akinc A.; Maier M.A.; Manoharan M.; et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol, 2019, 14(12): 1084-1087.
• 14.
  He H., Yuan D.F.; Wu Y.; et al. Pharmacokinetics and Pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs. Pharmaceutics, 2019, 11(3): 110.
• 15.
  Boafo G.F.; Thapa K.T.; Ekpo M.D.; et al. The role of cryoprotective agents in liposome stabilization and preservation. Int. J. Mol. Sci., 2022, 23(20): 12487.
• 16.
  Li Z.L.; Zhang Y.L.; Wurtz W.; et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol Med. Pulm. Drug Delivery, 2008, 21(3): 245-254.
• 17.
  LLS Health Technical Team. Excipients for solubility enhancement: enabling oral and injectable formulations. (accessed on 18 January 2023). https://www.lubrizol.com/Health/Blog/2022/03/Excipients-for-Solubility-Enhancement---Enabling-Oral-and-Injectable-Formulations.
• 18.
  Savjani K.T.; Gajjar A.K.; Savjani J.K. Drug solubility: importance and enhancement techniques. ISRN Pharm., 2012, 2012: 195727.
• 19.
  He H.S.; Lu Y.; Qi J.P.; et al. Adapting liposomes for oral drug delivery. Acta Pharm. Sin. B, 2019, 9(1): 36-48.
• 20.
  Giardiello M.; Liptrott N.J.; McDonald T.O.; et al. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nat. Commun., 2016, 7: 13184.
• 21.
  Bakshi R.P.; Tatham L.M.; Savage A.C.; et al. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nat. Commun., 2018, 9(1): 315.
• 22.
  World Health Organization. Cancer. (accessed on 2 December 2022). https://www.who.int/health-topics/cancer#tab=tab_3.
• 23.
  Carvalho C.; Santos R.X.; Cardoso S.; et al. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem., 2009, 16(25): 3267-3285.
• 24.
  Brown J.R.; Imam S.H. 5 recent studies on doxorubicin and its analogues. Prog. Med. Chem., 1985, 21: 169-236.
• 25.
  Yingchoncharoen P.; Kalinowski D.S.; Richardson D.R. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol. Rev., 2016, 68(3): 701-787.
• 26.
  Chang H.I.; Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomed., 2012, 7: 49-60.
• 27.
  O’Bryan R.M.; Luce J.K.; Talley R.W.; et al. Phase II evaluation of adriamycin in human neoplasia. Cancer, 1973, 32(1): 1-8.
• 28.
  Lefrak E.A.; Piťha J.; Rosenheim S.; et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 1973, 32(2): 302-314.
• 29.
  Chlebowski R.T. Adriamycin (doxorubicin) cardiotoxicity: a review. West. J. Med., 1979, 131(5): 364-368.
• 30.
  Cancer Chemotherapy Reports. U.S. department of health, education, and welfare, public health service, national institutes of health; 1975.
• 31.
  Park K. The beginning of the end of the nanomedicine hype. J. Controlled Release, 2019, 305: 221-222.
• 32.
  Hortobágyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs, 1997, 54(4): 1-7.
• 33.
  Waterhouse D.N.; Tardi P.G.; Mayer L.D.; et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf., 2001, 24(12): 903-920.
• 34.
  Birtle A.J. Anthracyclines and cardiotoxicity. Clin. Oncol., 2000, 12(3): 146-152.
• 35.
  Rivankar S. An overview of doxorubicin formulations in cancer therapy. J. Cancer Res. Ther., 2014, 10(4): 853-858.
• 36.
  Anon. Celsion Announces Enrollment Completion Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer–Duke OTC. (accessed on 12 December 2022). https://otc.duke.edu/news/celsion-announces-enrollment-completion-pivotal-phase-iii-optima-study-of-thermodox-in-primary-liver-cancer/.
• 37.
  Petersen G.H.; Alzghari S.K.; Chee W.; et al. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Controlled Release, 2016, 232: 255-264.
• 38.
  Morigi V.; Tocchio A.; Bellavite C.B.; et al. Nanotechnology in medicine: from inception to market domination. J. Drug Delivery, 2012, 2012: 389485.
• 39.
  Bharali D.J.; Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther., 2010, 128(2): 324-335.
• 40.
  Seigneuric R.; Markey L.; Nuyten D.S.A.; et al. From nanotechnology to nanomedicine: applications to cancer research. Curr. Mol. Med., 2010, 10(7): 640-652.
• 41.
  Rafiyath S.M.; Rasul M.; Lee B.; et al. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp. Hematol. Oncol., 2012, 1(1): 10.
• 42.
  Safra T. Cardiac safety of liposomal anthracyclines. The Oncologist, 2003, 8(S2): 17-24.
• 43.
  Šimůnek T.; Štěrba M.; Popelová O.; et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep., 2009, 61(1): 154-171.
• 44.
  Allen T.M.; Mumbengegwi D.R.; Charrois G.J.R. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res., 2005, 11(9): 3567-3573.
• 45.
  Safra T.; Muggia F.; Jeffers S.; et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol., 2000, 11(8): 1029-1033.
• 46.
  Kesterson J.P.; Odunsi K.; Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy, 2010, 56(2): 108-111.
• 47.
  Fukuda A.; Tahara K.; Hane Y.; et al. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS One, 2017, 12(9): e0185654.
• 48.
  Northfelt D.W.; Dezube B.J.; Thommes J.A.; et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol., 1998, 16(7): 2445-2451.
• 49.
  O’Brien M.E.R.; Wigler N.; Inbar M.; et al. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann. Oncol., 2004, 15(3): 440-449.
• 50.
  Swenson C.E.; Perkins W.R.; Roberts P.; et al. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). The Breast, 2001, 10, Supplement 2: 1-7.
• 51.
  Anon. FDA fast track designation for myocet for metastatic breast cancer. Oncology Times, 2010, 32(3): 24.
• 52.
  Immordino M.L.; Dosio F.; Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed., 2006, 1(3): 297-315.
• 53.
  Schnyder A.; Huwyler J. Drug transport to brain with targeted liposomes. NeuroRX, 2005, 2(1): 99-107.
• 54.
  Shao K.; Hou Q.S.; Duan W.; et al. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J. Controlled Release, 2006, 115(2): 150-157.
• 55.
  Saul J.M.; Annapragada A.; Natarajan J.V.; et al. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Controlled Release, 2003, 92(1/2): 49-67.
• 56.
  Itokazu M.; Kumazawa S.; Wada E.; et al. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Lett., 1996, 107(1): 11-18.
• 57.
  Bromberg L.; Alakhov V. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J. Controlled Release, 2003, 88(1): 11-22.
• 58.
  Zocchi E.; Tonetti M.; Polvani C.; et al. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proc. Natl. Acad. Sci. U. S. A., 1989, 86(6): 2040-2044.
• 59.
  Olivier J.C. Drug transport to brain with targeted nanoparticles. NeuroRX, 2005, 2(1): 108-119.
• 60.
  Petri B.; Bootz A.; Khalansky A.; et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Controlled Release, 2007, 117(1): 51-58.
• 61.
  Gaffi. Improving outcomes for patients with fungal infections across the world a road map for the next decade. (accessed on 15 December 2022). https://gaffi.org/wp-content/uploads/GAFFI_Road_Map_interactive-final0415.pdf.
• 62.
  Rodrigues M.L.; Nosanchuk J.D. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Neglected Trop. Dis., 2020, 14(2): e0007964.
• 63.
  Raut A.; Huy N.T. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir. Med., 2021, 9(8): e77.
• 64.
  Hoenigl M. Invasive fungal disease complicating coronavirus disease 2019: when it rains, it spores. Clin. Infect. Dis., 2021, 73(7): e1645-e1648.
• 65.
  Rivnay B.; Wakim J.; Avery K.; et al. Critical process parameters in manufacturing of liposomal formulations of amphotericin B. Int. J. Pharm., 2019, 565: 447-457.
• 66.
  Gallis H.A.; Drew R.H.; Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis., 1990, 12(2): 308-329.
• 67.
  Drugs.com. Fungizone prescribing information. (accessed on 12 December 2022). https://www.drugs.com/pro/fungizone.html.
• 68.
  Min Y.Z.; Caster J.M.; Eblan M.J.; et al. Clinical translation of nanomedicine. Chem. Rev., 2015, 115(19): 11147-11190.
• 69.
  Wingard J.R.; Kubilis P.; Lee L.; et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis., 1999, 29(6): 1402-1407.
• 70.
  Heinemann V.; Bosse D.; Jehn U.; et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob. Agents Chemother., 1997, 41(6): 1275-1280.
• 71.
  Jarvis J.N.; Lawrence D.S.; Meya D.B.; et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N. Engl. J. Med., 2022, 386(12): 1109-1120.
• 72.
  Rodrigues A.V.; Valério-Bolas A.; Alexandre-Pires G.; et al. Zoonotic visceral leishmaniasis: new insights on innate immune response by blood macrophages and liver Kupffer cells to Leishmania infantum parasites. Biology, 2022, 11(1): 100.
• 73.
  Boswell G.W.; Buell D.; Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol., 1998, 38(7): 583-592.
• 74.
  Wingard J.R.; White M.H.; Anaissie E.; et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis., 2000, 31(5): 1155-1163.
• 75.
  Lestner J.; McEntee L.; Johnson A.; et al. Experimental models of short courses of liposomal amphotericin B for induction therapy for cryptococcal meningitis. Antimicrob. Agents Chemother., 2017, 61(6): e00090-17.
• 76.
  Walsh T.J.; Yeldandi V.; McEvoy M.; et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother., 1998, 42(9): 2391-2398.
• 77.
  McLintock L.A.; Cook G.; Holyoake T.L.; et al. High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica, 2007, 92(4): 572-573.
• 78.
  World Health Organization. New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV. (accessed on 14 December 2022). https://www.who.int/news/item/20-04-2022-rapid-advice-new-guidelines-for-simpler-safer-treatment-for-cryptococcal-disease-in-plhiv.
• 79.
  Meyerhoff A. U.S. food and drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis., 1999, 28(1): 42-48.
• 80.
  Sundar S.; Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J. Global Infect. Dis., 2010, 2(2): 159-166.
• 81.
  MSF Access Campaign. Open letter to Gilead and Viatris: we need affordable treatments for the rise of serious invasive fungal diseases. (accessed on 25 January 2023). https://msfaccess.org/open-letter-ambisome-Gilead.